Scientists have identified that an experimental drug originally developed for spinal cord injuries may address several core features of Alzheimer's disease, including DNA damage and brain inflammation. According to the research findings, the treatment targets underlying mechanisms of the disease rather than merely managing its symptoms, a distinction that could reshape therapeutic approaches. The drug has already undergone initial safety testing in humans, a factor that may accelerate its path toward broader clinical evaluation and regulatory consideration.
The discovery adds to a growing body of evidence suggesting that Alzheimer's involves complex, interrelated processes beyond the accumulation of amyloid plaques, long the primary focus of drug development. By demonstrating effects on both DNA repair and neuroinflammation, the compound raises the possibility of a multi-target strategy against a condition that has resisted numerous high-profile treatment attempts. Researchers caution that further trials are needed to establish efficacy and long-term safety, but the existing human safety data offers a comparatively rapid route toward definitive testing.
Independent reporting synthesized from primary wires and global correspondents.